Logo image of TARS

TARSUS PHARMACEUTICALS INC (TARS) Stock Analyst Ratings

NASDAQ:TARS - Nasdaq - US87650L1035 - Common Stock - Currency: USD

42.685  +1.4 (+3.38%)

Buy % Consensus

87

ChartMill assigns a Buy % Consensus number of 87% to TARS. The Buy consensus is the weighted average rating of the current analysts ratings.

Analysts have set a mean price target forecast of 68.72. This target is 61% above the current price.
TARS was analyzed by 15 analysts. The buy percentage consensus is at 87. So analysts seem to be very confident about TARS.
In the previous month the buy percentage consensus was at a similar level.
TARS was analyzed by 15 analysts, which is quite many. So the average rating should be quite meaningful.
TARS Historical Analyst RatingsTARS Historical Analyst Buy, Sell and Hold Ratings and number of analysts.Historical Monthly Analyst Rating -51 -46 -41 -36 -31 -26 -21 -16 -11 -6 -1 5 10

Price Target & Forecast

Price Low Median Mean High 42.6944.4473.9568.7288.20 - 4.11% 73.25% 61.00% 106.63%
TARS Current Analyst RatingTARS Current Analyst Buy, Sell and Hold Ratings.Current Analyst Rating Strong Buy Buy Hold Sell Strong Sell 2 4 6
Up and Down Grades
Date Firm Action Rating
2025-02-26 Barclays Maintains Overweight -> Overweight
2025-02-26 HC Wainwright & Co. Reiterate Buy -> Buy
2025-02-24 Guggenheim Reiterate Buy -> Buy
2025-02-10 Guggenheim Reiterate Buy -> Buy
2025-01-27 Barclays Maintains Overweight -> Overweight
2025-01-22 Oppenheimer Maintains Outperform -> Outperform
2024-11-15 Goldman Sachs Maintains Neutral -> Neutral
2024-11-14 Oppenheimer Maintains Outperform -> Outperform
2024-08-09 Oppenheimer Reiterate Outperform -> Outperform
2024-05-13 HC Wainwright & Co. Maintains Buy -> Buy
2024-05-10 Barclays Maintains Overweight -> Overweight
2024-05-09 Oppenheimer Maintains Outperform -> Outperform
2024-03-06 Jefferies Maintains Buy -> Buy
2024-02-29 Goldman Sachs Maintains Neutral -> Neutral
2024-02-28 Oppenheimer Reiterate Outperform -> Outperform
2024-02-28 Barclays Maintains Overweight -> Overweight
2024-02-28 HC Wainwright & Co. Maintains Buy -> Buy
2023-11-20 Goldman Sachs Initiate Neutral
2023-11-10 HC Wainwright & Co. Maintains Buy -> Buy
2023-09-11 Guggenheim Maintains Buy -> Buy
2023-08-14 Guggenheim Reiterate Buy -> Buy
2023-08-11 HC Wainwright & Co. Maintains Buy -> Buy
2023-07-26 HC Wainwright & Co. Maintains Buy -> Buy
2023-07-18 William Blair Initiate Outperform
2023-06-26 HC Wainwright & Co. Maintains Buy -> Buy
2023-06-16 Guggenheim Maintains Buy
2023-05-18 Guggenheim Initiate Buy
2023-05-08 Oppenheimer Reiterate Outperform
2023-03-15 HC Wainwright & Co. Reiterate Buy
2022-08-01 Barclays Initiate Overweight